Management of joint replacement surgery with a von Willebrand factor product with a low FVIII content in von Willebrand disease patients

被引：0
|
作者：
Borel-Derlon, A. [1 ]
Federici, A. B. [2 ]
Goudemand, J. [3 ]
Roussel-Robert, V [4 ]
Chatelanaz, C. [6 ]
Henriet, C. [6 ]
Bridey, F. [6 ]
机构：
[1] Univ Hosp, Haemophilia Treatment Ctr, Caen, France
[2] Univ Milan, Bianchi Bonomi Haemophilia & Thrombosis Ctr, I-20122 Milan, Italy
[3] Univ Hosp Lille, Haemophilia Treatment Ctr, Lille, France
[4] Univ Hosp Paris Cochin, Haemophilia Treatment Ctr, Paris, France
[5] Haemophilia Treatment Ctr, Montpellier, France
[6] LFB, Les Ulis, France
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2011年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-WE-469
引用
收藏
页码：668 / 668
页数：1
相关论文
共 50 条
  • [31] INHIBITION OF WILLEBRAND FACTOR IN VON WILLEBRAND DISEASE
    MARAGALL, S
    CASTILLO, R
    ORDINAS, A
    LIENDO, F
    RODRIGUEZ, M
    THROMBOSIS RESEARCH, 1979, 14 (2-3) : 495 - 500
  • [32] Studies of multimerin in patients with von Willebrand disease and platelet von Willebrand factor deficiency
    Chen, CI
    Federici, AB
    Cramer, EM
    Canciani, MT
    Harrison, P
    Zheng, SL
    Massé, JM
    Mannucci, PM
    Hayward, CPM
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (01) : 20 - 28
  • [33] Investigation of von Willebrand factor gene mutations in Korean von Willebrand disease patients
    Song, Jaewoo
    Choi, Jong Rak
    Song, Kyung Soon
    KOREAN JOURNAL OF LABORATORY MEDICINE, 2007, 27 (03): : 169 - 176
  • [34] THE UTILITY OF THE DDAVP CHALLENGE TEST IN PATIENTS WITH LOW VON WILLEBRAND FACTOR LEVELS AND VON WILLEBRAND DISEASE (VWD)
    Archer, Natasha
    Samnaliev, Mihail
    Grace, Rachael
    Brugnara, Carlo
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S20 - S20
  • [35] Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery
    Di Paola, J.
    Lethagen, S.
    Gill, J.
    Mannucci, P.
    Manco-Johnson, M.
    Bernstein, J.
    Nichols, W. L.
    Bergman, G. E.
    HAEMOPHILIA, 2011, 17 (05) : 752 - 758
  • [36] Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor
    Peyvandi, Flora
    Kouides, Peter
    Turecek, Peter L.
    Dow, Edward
    Berntorp, Erik
    BLOOD REVIEWS, 2019, 38
  • [37] Differentiation of Patients with Symptomatic Low von Willebrand Factor from Those with Asymptomatic Low von Willebrand Factor
    Grabowski, Eric F.
    Van Cott, Elizabeth M.
    Bornikova, Larissa
    Boyle, Daniel C.
    Silva, Raisa Lomanto
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (05) : 793 - 804
  • [38] Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease
    Batlle, Javier
    Fernanda Lopez-Fernandez, Maria
    Loures Fraga, Esther
    Rodriguez Trillo, Angela
    Almudena Perez-Rodriguez, Maria
    BLOOD COAGULATION & FIBRINOLYSIS, 2009, 20 (02) : 89 - 100
  • [39] Individually tailored prophylaxis in Type 3 von Willebrand Disease patients: efficacy and safety of a von Willebrand Factor concentrate with a low factor VIII content
    Gouider, E.
    Peerlinck, K.
    Hermans, C.
    Gadisseur, A.
    Klukowska, A.
    Knuchel, N.
    Stevens, W.
    Matysiak, M.
    Meddeb, B.
    Henriet, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 945 - 945
  • [40] The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor
    Pergantou, H.
    Xafaki, P.
    Adamtziki, E.
    Koletsi, P.
    Komitopoulou, A.
    Platokouki, H.
    HAEMOPHILIA, 2012, 18 (03) : e66 - e67
12345